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Acute Encephalitis Associated with SARS-CoV-2 Confirmed 
in Cerebrospinal Fluid: First Case in Malaysia
Dear Editor, 
A 69-year-old male with hypertension and atrial fibrillation presented with a 4-day histo-
ry of fever, cough, and breathlessness, and subsequently developed disorientation and con-
fusion for 1 day. On arrival, his Glasgow Coma Scale was 12/15 (E4, V3, and M5). His body 
temperature was 37.5°C, blood pressure was 136/60 mm Hg, pulse rate was 72 beats/min , and 
SpO2 was 98%, with a nasal prong of 3 L/min. There were no symptoms of meningism or long-
tract signs. On the following day he became increasingly restless and breathless, and required 
a high-flow-rate nasal cannula to maintain adequate oxygenation. A diagnosis of Coronavi-
rus disease-2019 (COVID-19) was established based on positivity when using an antigen 
rapid testing kit (SD Biosensor, Inc., Suwon, Korea). However, severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) was not detected when the polymerase chain reaction 
(PCR) was applied to the nasopharyngeal swab sample. High-resolution CT of his lungs 
showed subpleural ground-glass opacities with reticulation on the background of chronic 
lung changes. Noncontrast brain CT only revealed an old right lenticular infarct. The open-
ing pressure in lumbar puncture was 9.5 cmH2O. His cerebrospinal fluid (CSF) was clear, 
with a protein level of 1.16 g/L, and the CSF/serum glucose ratio was 0.58. A white blood cell 
count of 50 cells/mm3 with 100% lymphocytes was seen in the CSF. SARS-CoV-2 was de-
tected in his CSF using PCR with a cycle threshold value of 36.08 and the ORF1ab gene. The 
results of other CSF analyses were unremarkable. 
He was treated with tablet favipiravir at 1800 mg b.i.d. for 1 day followed by 900 mg b.i.d. 
for 5 days, antituberculosis agents (in view of a high protein level in the CSF with 100% lym-
phocytes), and intravenous dexamethasone at 8 mg t.d.s., which was later tapered. After 1 
week, upon positivity in PCR testing of CSF for SARS-CoV-2, a diagnosis of COVID-
19-associated encephalitis was made, and antituberculosis drugs were discontinued. Intra-
venous methylprednisolone was applied at 500 mg daily for 3 days followed by a tapering 
dose of oral prednisolone over 24 days. By the second day of methylprednisolone adminis-
tration, he regained full consciousness after having been disorientated for 10 days. Electro-
encephalography (EEG) and brain MRI were not available at our center during his admis-
sion. EEG findings were normal at a clinic follow-up performed in the third week of his 
illness. Brain MRI was unremarkable after 1 month of illness. He subsequently remained 
well with no neurological sequelae. 
Neurological manifestations associated with COVID-19 are reported to range from non-
specific symptoms such as dizziness, headache, and fatigue, to diseases such as Guillain–
Barré syndrome, encephalitis, myelitis, and acute necrotizing hemorrhagic encephalopathy.1 
Mao et al.2 reported that 36.4% of hospitalized COVID-19 patients had neurological mani-
festations. Moriguchi et al.3 and our case have demonstrated that encephalitis is most likely 
due to neurotropism of SARS-CoV-2, since the virus was detected in the CSF. Wang et al.1 
found only 1 case among 41 reviewed articles in which SARS-CoV-2 was detected in the CSF. 
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